The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Apr. 27, 2020
Applicant:

Merck Sharp & Dohme Llc, Rahway, NJ (US);

Inventors:

Ian M. Bell, Harleysville, PA (US);

Brian T. Campbell, Doylestown, PA (US);

Brendan M. Crowley, Collegeville, PA (US);

James Fells, Hillsborough, NJ (US);

Kenneth J. Leavitt, Garnet Valley, PA (US);

Anthony J. Roecker, Harleysville, PA (US);

Andrew John Harvey, Paddington Spring Hill, AU;

Belinda C. Huff, Thebarton, AU;

Dharam Paul, Thebarton, AU;

Christophe Morice, Illkirch, FR;

Christophe Joseph, Illkirch, FR;

Patrick Bazzini, Illkirch, FR;

Jean-Marie Contreras, Illkirch, FR;

Fabrice Garrido, Illkirch, FR;

Aurelie Witzel, Illkirch, FR;

Assignee:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 221/20 (2006.01); A61K 31/438 (2006.01); A61K 31/444 (2006.01); A61K 45/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
C07D 221/20 (2013.01); A61K 31/438 (2013.01); A61K 31/444 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 413/12 (2013.01);
Abstract

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation


Find Patent Forward Citations

Loading…